Literature DB >> 23928571

Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice.

Susan F Hudachek1, Daniel L Gustafson.   

Abstract

Combination therapy is increasingly being utilized for the treatment of metastatic breast cancer. However, coadministration of drugs, particularly agents that are substrates for or inhibitors of p-glycoprotein, can result in increased tissue toxicity. Unfortunately, determination of levels of chemotherapeutics in human tissues is challenging, and plasma drug concentrations are not always indicative of tissue toxicokinetics or toxicodynamics, especially when tissue penetration is altered. The aim of the present work was to determine whether concomitant administration of compounds currently being combined in clinical trials for metastatic breast cancer treatment alters plasma and tissue pharmacokinetics in mice if both agents are p-glycoprotein substrates and/or inhibitors. Accordingly, we investigated the pharmacokinetic interactions of the classic cytotoxics and p-glycoprotein substrates docetaxel and doxorubicin when administered concurrently with the targeted agent and p-glycoprotein inhibitor lapatinib. Our time-course plasma and tissue distribution studies showed that coadministration of lapatinib with doxorubicin did not appreciably alter the pharmacokinetics of this anthracycline in the plasma or six tissues evaluated in mice, presumably because, at doses relevant to human exposure, lapatinib inhibition of p-glycoprotein did not significantly alter doxorubicin transport out of these tissue compartments. However, combining lapatinib with docetaxel significantly increased intestinal exposure to this chemotherapeutic, which has clinical implications for enhancing gastrointestinal toxicity. The significant lapatinib-docetaxel interaction is likely CYP3A4-mediated, suggesting that caution should be exercised when this combination is administered, particularly to patients with compromised CYP3A activity, and recipients should be monitored closely for enhanced toxicity, particularly for adverse effects on the intestine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23928571      PMCID: PMC4694043          DOI: 10.1097/CAD.0b013e3283645e1a

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  45 in total

1.  Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS).

Authors:  Feng Bai; Burgess B Freeman; Charles H Fraga; Maryam Fouladi; Clinton F Stewart
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-12-20       Impact factor: 3.205

2.  P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain.

Authors:  E Beaulieu; M Demeule; L Ghitescu; R Béliveau
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

3.  Role of P-glycoprotein in distribution of nelfinavir across the blood-mammary tissue barrier and blood-brain barrier.

Authors:  Jeffrey E Edwards; Jane Alcorn; Juoko Savolainen; Bradley D Anderson; Patrick J McNamara
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Pharmacokinetics of combined doxorubicin and paclitaxel in mice.

Authors:  Daniel L Gustafson; Andrea L Merz; Michael E Long
Journal:  Cancer Lett       Date:  2005-04-08       Impact factor: 8.679

5.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.

Authors:  M F Paine; M Khalighi; J M Fisher; D D Shen; K L Kunze; C L Marsh; J D Perkins; K E Thummel
Journal:  J Pharmacol Exp Ther       Date:  1997-12       Impact factor: 4.030

6.  Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver.

Authors:  M Shou; M Martinet; K R Korzekwa; K W Krausz; F J Gonzalez; H V Gelboin
Journal:  Pharmacogenetics       Date:  1998-10

7.  Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.

Authors:  Patricia M LoRusso; Suzanne F Jones; Kevin M Koch; Nikita Arya; Ronald A Fleming; Jill Loftiss; Lini Pandite; Shirish Gadgeel; Barbara L Weber; Howard A Burris
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

8.  Cardiotoxicity in the SCID mouse following administration of doxorubicin and cyclosporin A.

Authors:  W T Bellamy; Y M Peng; A Odeleye; L Ellsworth; M J Xu; T M Grogan; R S Weinstein
Journal:  Anticancer Drugs       Date:  1995-12       Impact factor: 2.248

9.  Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833.

Authors:  O Gonzalez; T Colombo; M De Fusco; L Imperatori; M Zucchetti; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.

Authors:  J van Asperen; O van Tellingen; F Tijssen; A H Schinkel; J H Beijnen
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

View more
  2 in total

1.  Influence of Concomitant Polypharmacy on Docetaxel-induced Febrile Neutropenia.

Authors:  Katsuya Makihara; Yuka Shimeda; Tomokazu Matsumura
Journal:  Cancer Diagn Progn       Date:  2021-07-03

Review 2.  Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines.

Authors:  L M Greene; S Butini; G Campiani; D C Williams; D M Zisterer
Journal:  J Cancer       Date:  2016-12-04       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.